Antimuscarinic Therapy for OAB Linked to Depression in Women

This article originally appeared here.
Clinicians should be alert to the relationship between antimuscarinics usage and depressive disorder in OAB women and provide appropriate instructions for these patients.
Clinicians should be alert to the relationship between antimuscarinics usage and depressive disorder in OAB women and provide appropriate instructions for these patients.

(HealthDay News) — Women with overactive bladder (OAB) syndrome treated with antimuscarinics have increased subsequent risk of depressive disorder, according to a study published online in the Journal of Clinical Pharmacology.

Shiu-Dong Chung, PhD, MD, from the Far Eastern Memorial Hospital in Taiwan, and colleagues conducted a retrospective cohort study to examine the correlation between antimuscarinic use and subsequent risk of depressive disorder. Data were obtained from the Taiwan Longitudinal Health Insurance Database 2005 for 1952 women with OAB who received antimuscarinics and 9760 who did not receive antimuscarinics. The women were followed for 3 years from the index date.

The researchers found that the adjusted hazard ratio for depressive disorder was 1.38 (95% confidence interval, 1.15 to 1.64) for women with OAB who received antimuscarinics versus those who did not receive antimuscarinics. For women with OAB aged 18 to 39, 40 to 59, and ≥60 years who received antimuscarinics, the adjusted hazard ratios for subsequent depressive disorder were 1.83 (95% confidence interval, 1.27 to 2.64), 1.36 (95% confidence interval, 1.03 to 1.81), and 1.16 (95% confidence interval, 0.86 to 1.56), respectively.

"Clinicians should be alert to the relationship between antimuscarinics usage and depressive disorder in OAB women and provide appropriate instructions for these patients," the authors write.

Reference

  1. Chung SD, Weng SS, Huang CY, et al. Antimuscarinic Use in Females With Overactive Bladder Syndrome Increases the Risk of Depressive Disorder: A 3-Year Follow-up Study. J Clin Pharmacol. 5 April 2017. doi: 10.1002/jcph.890

Related Slideshows

You must be a registered member of Renal and Urology News to post a comment.